What is Vistagen's latest dividend and current dividend yield?

What is Vistagen's gross profit margin?

What were the key takeaways from Vistagen’s earnings call?

What is the revenue and EPS growth rate for Vistagen year over year?

What guidance did Vistagen's management provide for the next earnings period?

What is the market's earnings forecast for Vistagen next quarter?

Did Vistagen beat or miss consensus estimates last quarter?

What factors drove the changes in Vistagen's revenue and profit?

- **PALISADE-3 Completion**: Randomized portion finalized with operational refinements for PALISADE-4, including AI/ML-driven statistical model optimization.
- **Women's Health Milestone**: Refisolone IND submission planned for Q2 2026, targeting menopausal hot flashes as a hormone-free alternative.
- **Cash Position Strength**: $61.8 million as of Q3 2026, supporting clinical trials and cost-efficient operations.
- **Regulatory Risk**: FDA approval of PALISADE-4 statistical modifications required; PALISADE-2 alone insufficient for NDA submission.
- **Enrollment Stability**: PALISADE-4 recruitment unaffected by PALISADE-3 results; open-label extension provides real-world safety insights.

### Core Details - Detail Page
**【Management Opening Remarks】**
- Vistagen filed its Q3 2026 Form 10-Q and issued a press release on December 31, 2025, highlighting progress in its neuroscience pipeline.
- The company emphasized forward-looking statements' risks, including clinical trial outcomes and regulatory uncertainties.
- Cash position as of Q3 2026: $61.8 million, supporting ongoing clinical trials and operational efficiency.

**【CEO Commentary】**
- **PALISADE-3 Phase III Trial**: Completed randomized portion with moderate refinements for PALISADE-4, including site retraining and operational enhancements.
- **AI/ML Analysis**: Collaborating with third-party experts to identify placebo response predictors and optimize statistical models for FDA discussions.
- **Women's Health Program**: Received USAN adoption for refisolone (formerly PH80), with IND submission planned for Q2 2026 for menopausal hot flashes.
- **Open-Label Extension (OLE)**: Evaluating long-term safety and efficacy of fasedienol in real-world settings using validated anxiety metrics.

**【CFO Financial Commentary】**
- Q3 2026 cash balance: $61.8 million, supporting PALISADE-4 execution and women's health program advancement.
- Implemented cost-saving measures to extend operational runway and maintain strategic flexibility.

**【Q&A Highlights】**
- **PALISADE-3 Data Analysis**: Ongoing AI-driven analysis to identify covariates for statistical model refinement; no individual timepoint curves disclosed.
- **SAP Modifications**: Any changes to PALISADE-4's Statistical Analysis Plan require FDA resubmission and approval; enrollment target remains unchanged.
- **Regulatory Path Forward**: PALISADE-4 success would enable NDA submission; PALISADE-2 alone insufficient for approval without totality of evidence.
- **Enrollment Status**: PALISADE-4 enrollment unaffected by PALISADE-3 results; recruitment proceeding as planned.
- **Financial Impact**: Shares outstanding at 39.7 million (Q3 2026) vs. weighted average 42 million, driven by prefunded warrants.


Vistagen Therapeutics, Inc. (VTGN) Q3 2026 Earnings Call Transcript

- **Trial Milestone**: PALISADE-3 Phase III trial completed; top-line results expected by end of 2025.
- **Cash Position**: $77.2 million in cash to support U.S. registration efforts.
- **Pipeline Expansion**: itruvone and PH80 in Phase III, targeting depression and menopause.
- **Commercial Focus**: Exploring partnerships for U.S. launch, leveraging digital health trends.
- **FDA Readiness**: Preparing for potential NDA submission in early 2026.

**【CEO Summary Section】**
- **PALISADE-3 Trial Completion**: Last patient completed the randomized double-blind phase of the Phase III trial for fasedienol, targeting social anxiety disorder (SAD). Top-line results expected by end of 2025.
- **Pipeline Progress**: PALISADE-4 Phase III trial ongoing; itruvone (major depressive disorder) and PH80 (menopausal hot flashes) in Phase III development.
- **Financial Position**: $77.2 million in cash as of September 30, 2025, sufficient to cover U.S. registration-directed PALISADE program costs.
- **Board Update**: Paul Edick joined the Board, bringing FDA and commercial launch expertise.

**【Q&A Highlights】**
- **PALISADE-3 Timeline**: Top-line results to be released by end of 2025; safety and efficacy data from the public speaking challenge (primary endpoint) and secondary endpoints (CGI-I, PGI-C) will be reported.
- **Site Management**: 1-2 sites terminated due to enrollment challenges; others wound down as the trial concluded.
- **Commercial Strategy**: Considering partnerships for U.S. launch; leveraging digital health trends and consumer engagement for patient access.
- **FDA Interaction**: Planning for NDA submission if PALISADE-3 is positive, with interactions expected in early 2026.
- **Usage Patterns**: Open-label data shows weekday utilization, aligning with real-world social stressors.


Vistagen Therapeutics, Inc. (VTGN) Q2 2026 Earnings Call Transcript

- **Phase III Milestones**: Q4 2025 top-line data for fasedienol in SAD; Q1 2026 readout for second trial.
- **Pipeline Growth**: IND submissions for Itruvone (depression) and PH80 (hot flashes) expected in Q4 2025.
- **Financial Stability**: $63.2M cash reserves support R&D through 2026; net loss of $15.1M reflects strategic investment.
- **Clinical Strength**: 80%+ OLE conversion rates; no safety red flags in 30,000+ doses.
- **Market Differentiation**: Non-systemic delivery, rapid onset, and avoidance of systemic side effects set fasedienol apart from competitors.

**【CEO Summary Section】**
- **Fasedienol Phase III Progress**: Top-line data expected in Q4 2025 (PALISADE-3) and Q1 2026 (PALISADE-4) for acute treatment of social anxiety disorder (SAD). Positive PALISADE-2 results support potential FDA submission.
- **Pipeline Expansion**: 
  - Itruvone (major depressive disorder) IND submission planned for Q4 2025.
  - PH80 (menopausal hot flashes) IND submission expected in Q4 2025.
- **Operational Strength**: 80%+ conversion rate to open-label extension (OLE) in Phase III trials, meeting ICH safety requirements.
- **New Leadership**: Elissa Cote, Chief Corporate Development Officer, to drive commercialization and strategic growth.

**【CFO Financial Commentary】**
- **Q1 2026 Financials**: 
  - R&D expenses: $11.7M (vs. $7.6M YoY), driven by PALISADE program.
  - G&A expenses: $4.4M (stable vs. $4.6M YoY).
  - Net loss: $15.1M (vs. $10.7M YoY).
  - Cash reserves: $63.2M as of June 30, 2025.
- **Funding Position**: Sufficient liquidity to support Phase III completion and pipeline expansion.

**【Q&A Key Highlights】**
- **Enrollment & Retention**: 
  - PALISADE-3 and 4 enrollment ongoing; no protocol changes anticipated.
  - 80%+ subjects convert to OLE, with retention rates exceeding prior trials.
- **Efficacy & Safety**: 
  - No statistically significant gender differences in efficacy (PALISADE-2).
  - Baseline SUDS scores ~80-85, consistent across trials.
  - Safety profile: Headache (8.7%) most common adverse event; no abuse liability signals.
- **Competitive Landscape**: Differentiation via nose-to-brain delivery, rapid onset, and non-systemic mechanism vs. oral therapies.
- **Site Management**: Proactive site oversight; 3 recruitment programs to optimize enrollment. Sites terminated for poor performance or rater turnover.


Vistagen Therapeutics, Inc. (VTGN) Q1 2026 Earnings Call Transcript

- **Fasedienol Milestone**: Q4 2025 data readout for PALISADE-3 could make fasedienol the first FDA-approved acute SAD treatment.
- **Pipeline Expansion**: PH80 IND submission in H2 2025 for women's health; itruvone shows promise for MDD without systemic side effects.
- **FDA Support**: Agency emphasizes modernizing pathways for novel therapies; no changes to Vistagen's review teams.
- **Financial Resilience**: $80.5M cash reserve supports clinical programs despite FY2025 net loss of $51.4M.

**【CEO Summary Section】**
- **Fasedienol Phase III Progress**: PALISADE-3 trial on track for Q4 2025 readout; PALISADE-4 expected in H1 2026. Fasedienol aims to be the first FDA-approved acute treatment for social anxiety disorder (SAD), targeting 31M U.S. adults.
- **Diversified Pipeline**: 5 clinical-stage pherine candidates, including PH80 for women's health (menopausal hot flashes, PMDD) and itruvone for major depressive disorder (MDD). PH80 IND submission anticipated in H2 2025.
- **FDA Regulatory Updates**: CEO Listening Tour highlights FDA's focus on modernizing pathways for novel MOAs; no changes to review teams for Vistagen programs.

**【CFO Financial Commentary】**
- **R&D Expenses**: $39.4M (FY2025) vs. $20M (FY2024), driven by PALISADE program and PH80 IND preparation.
- **G&A Expenses**: $17.1M (FY2025) vs. $14.1M (FY2024), due to headcount and professional fees.
- **Cash Position**: $80.5M as of March 31, 2025, supporting ongoing clinical development.

**【Q&A Key Points】**
- **PALISADE-4 Timing**: Delays due to enhanced eligibility criteria and secondary review processes; prioritizes study rigor over speed.
- **FDA Alignment**: FDA acknowledges SAD as a serious unmet need; no direct alignment on fasedienol's innovation voucher eligibility.
- **Competitive Landscape**: Differentiated MOA (nonsystemic intranasal delivery) reduces side effects compared to traditional antidepressants.

Vistagen Therapeutics, Inc. (VTGN) Q4 2025 Earnings Call Transcript

- **Fasedienol Clinical Milestone**: Phase 3 trials on track for H2 2025 readouts, positioning for SAD treatment approval.
- **Pipeline Expansion**: Five clinical-stage candidates with differentiated non-systemic mechanisms.
- **Financial Resilience**: $88.6M cash runway supports aggressive R&D spend (+151% YoY).

**【CEO Summary Section】**
- Fasedienol's Phase 3 trials (PALISADE-3 and -4) are advancing toward top-line data release in H2 2025, with potential for FDA NDA submission for acute SAD treatment.
- Initiated a repeat-dose Phase 2 study for fasedienol to evaluate safety and efficacy of multiple administrations.
- Pipeline expansion includes IND-prep for itruvone (MDD) and PH80 (menopausal hot flashes), alongside five clinical-stage pherine candidates with positive safety profiles.

**【CFO Financial Commentary】**
- Q3 2025 R&D expenses: $11.3M (+151% YoY) driven by Phase 3 trials and IND-enabling studies.
- G&A expenses: $4.0M (+5% YoY) due to headcount growth.
- Cash reserves: $88.6M as of Dec 31, 2024, supporting ongoing clinical development.

**【Q&A Key Insights】**
- Execution confidence: Internal team oversight reduces variability, with rigorous protocol adherence and real-time site training.
- Competitive differentiation: Intranasal pherine mechanism avoids systemic absorption, targeting nose-to-brain neurocircuitry for rapid onset without black box warnings.
- Regulatory path: Repeat-dose study aims to inform labeling for on-demand use, with no safety concerns identified to date.

Actual							-15	-2.1	-1.5	-2.1	-6	-1.2	-2.1	-1.5	-2.4	-3	-2.4	-1.5	-1.61	-0.94	-0.66	-0.22	0.3	-0.35	-0.42	-0.46		-0.47	-0.54	-0.45
Forecast							-2.4	-2.1	-0.7	-1.6	-1.425	-1.6	-1.725	-2.175	-1.725	-2.4	-2	-2.049	-1.5	-0.86	-0.68	-0.3025	-0.3625	-0.4029	-0.3908	-0.5097		-0.4733	-0.4767	-0.4869
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-525.00%	0.00%	-114.29%	-31.25%	-321.05%	+25.00%	-21.74%	+31.03%	-39.13%	-25.00%	-20.00%	+26.79%	-7.33%	-9.30%	+2.94%	+27.27%	+182.76%	+13.13%	-7.47%	+9.75%	0.00%	+0.70%	-13.28%	+7.58%

Actual	--	--	--	--	--	--	--	0	334.00K	313.60K	442.00K	354.10K	358.00K	357.90K	39.00K	310.10K	-892.50K	179.60K	172.70K	177.60K	277.70K	411.40K	194.00K	84.00K	183.00K	234.00K	--	244.00K	258.00K	303.00K
Forecast	--	--	--	--	--	--	0	0	2.50M	334.00K	304.53K	394.63K	351.37K	338.67K	338.63K	238.63K	310.05K	310.10K	179.60K	184.60K	184.60K	726.00K	405.70K	298.65K	224.67K	308.50K	--	647.00K	364.25K	364.43K
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-86.64%	-6.11%	+45.14%	-10.27%	+1.89%	+5.68%	-88.48%	+29.95%	-387.86%	-42.08%	-3.84%	-3.79%	+50.43%	-43.33%	-52.18%	-71.87%	-18.55%	-24.15%	0.00%	-62.29%	-29.17%	-16.86%

VTGN

VTGN fundamentals

VTGN Q3 2026 Earnings

Earnings Call

You can ask Aime

VTGN

VTGN fundamentals

VTGN Q3 2026 Earnings

Earnings Call

VTGN Earnings Call Summary for Q3/20265:00 PM on Feb 12, 2026

VTGN Earnings Call Summary for Q2/20265:00 PM on Nov 13, 2025

VTGN Earnings Call Summary for Q1/20265:00 PM on Aug 7, 2025

VTGN Earnings Call Summary for Q4/20255:00 PM on Jun 17, 2025

VTGN Earnings Call Summary for Q3/20255:00 PM on Feb 13, 2025

You can ask Aime